InfuSystem (INFU) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 09, 2021
Document Information [Line Items]
Entity Central Index Key	0001337013
Entity Registrant Name	InfuSystem Holdings, Inc
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-35020
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3341405
Entity Address, Address Line One	3851 West Hamlin Road
Entity Address, City or Town	Rochester Hills
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48309
City Area Code	248
Local Phone Number	291-1210
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	INFU
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,568,489

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 164	$ 9,648
Accounts receivable, net	15,525	14,720
Inventories	3,722	3,001
Other current assets	2,264	2,402
Total current assets	21,675	29,771
Medical equipment for sale or rental	2,955	1,603
Medical equipment in rental service, net of accumulated depreciation	35,401	35,611
Property & equipment, net of accumulated depreciation	4,319	4,296
Goodwill	3,711	0
Intangible assets, net	13,053	11,177
Operating lease right of use assets	4,102	4,461
Deferred income taxes	10,612	9,967
Other assets	169	105
Total assets	95,997	96,991
Current liabilities:
Accounts payable	7,804	6,779
Current portion of long-term debt	520	9,423
Other current liabilities	7,525	6,795
Total current liabilities	15,849	22,997
Long-term debt, net of current portion	31,940	29,378
Operating lease liabilities, net of current portion	3,508	3,864
Total liabilities	51,297	56,239
Stockholders’ equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued	0	0
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 24,084,117 and 20,565,628, respectively, as of June 30, 2021, and issued and outstanding 23,816,193 and 20,297,704, respectively, as of December 31, 2020	2	2
Additional paid-in capital	87,213	84,785
Accumulated other comprehensive income	39	0
Retained deficit	(42,554)	(44,035)
Total stockholders’ equity	44,700	40,752
Total liabilities and stockholders’ equity	$ 95,997	$ 96,991

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	24,084,117	23,816,193
Common stock, shares outstanding (in shares)	20,565,628	20,297,704

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net revenues	$ 24,834	$ 25,999	$ 49,297	$ 47,552
Cost of revenues	9,784	10,021	19,671	18,911
Gross profit	15,050	15,978	29,626	28,641
Selling, general and administrative expenses:
Provision for doubtful accounts	(39)	238	(109)	523
Amortization of intangibles	1,096	1,075	2,139	2,150
Selling and marketing	2,680	2,449	5,056	5,067
General and administrative	10,617	7,710	20,971	16,362
Total selling, general and administrative	14,354	11,472	28,057	24,102
Operating income	696	4,506	1,569	4,539
Other expense:
Interest expense	(317)	(332)	(639)	(735)
Other expense	(37)	(9)	(106)	(28)
Income before income taxes	342	4,165	824	3,776
Benefit from (provision for) income taxes	478	(25)	657	(54)
Net income	$ 820	$ 4,140	$ 1,481	$ 3,722
Net income per share:
Basic (in dollars per share)	$ 0.04	$ 0.21	$ 0.07	$ 0.19
Diluted (in dollars per share)	$ 0.04	$ 0.19	$ 0.07	$ 0.17
Weighted average common shares outstanding:
Basic (in shares)	20,487,845	20,082,590	20,413,416	20,000,444
Diluted (in shares)	22,065,486	21,635,705	22,017,455	21,598,071
Comprehensive income:
Net income	$ 820	$ 4,140	$ 1,481	$ 3,722
Other comprehensive income:
Unrealized (loss) gain on hedges	(106)	0	52	0
Provision for income tax on unrealized hedge gain or loss	(13)	0	(13)	0
Net comprehensive income	$ 701	$ 4,140	$ 1,520	$ 3,722

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balances (in shares) at Dec. 31, 2019	23,401,000				(3,518,000)
Beginning balance at Dec. 31, 2019	$ 2	$ 83,699	$ (61,367)	$ 0	$ 0	$ 22,334
Stock-based shares issued upon vesting - gross (in shares)	292,000				0
Stock-based shares issued upon vesting - gross	$ 0	0	0	0	$ 0	0
Stock-based compensation expense	$ 0	563	0	0	$ 0	563
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(84,000)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(741)	0	0	$ 0	(741)
Net income	$ 0	0	3,722	0	$ 0	3,722
Employee stock purchase plan (in shares)	14				0
Employee stock purchase plan	$ 0	74	0	0	$ 0	74
Common stock issued (in shares)	28,000				0
Common stock issued	$ 0	250	0	0	$ 0	250
Balances (in shares) at Jun. 30, 2020	23,651,000				(3,518,000)
Ending balance at Jun. 30, 2020	$ 2	83,845	(57,645)	0	$ 0	26,202
Balances (in shares) at Mar. 31, 2020	23,543,000				(3,518,000)
Beginning balance at Mar. 31, 2020	$ 2	83,803	(61,785)	0	$ 0	22,020
Stock-based shares issued upon vesting - gross (in shares)	140,000				0
Stock-based shares issued upon vesting - gross	$ 0	0	0	0	$ 0	0
Stock-based compensation expense	$ 0	357	0	0	$ 0	357
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(32,000)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(315)	0	0	$ 0	(315)
Net income	$ 0	0	4,140	0	$ 0	4,140
Balances (in shares) at Jun. 30, 2020	23,651,000				(3,518,000)
Ending balance at Jun. 30, 2020	$ 2	83,845	(57,645)	0	$ 0	26,202
Balances (in shares) at Dec. 31, 2020	23,816,000				(3,518,000)
Beginning balance at Dec. 31, 2020	$ 2	84,785	(44,035)	0	$ 0	40,752
Stock-based shares issued upon vesting - gross (in shares)	309,000				0
Stock-based shares issued upon vesting - gross	$ 0	393	0	0	$ 0	393
Stock-based compensation expense	$ 0	3,007	0	0	$ 0	3,007
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(57,000)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(1,141)	0	0	$ 0	(1,141)
Net income	$ 0	0	1,481	0	$ 0	1,481
Employee stock purchase plan (in shares)	16,000				0
Employee stock purchase plan	$ 0	169	0	0	$ 0	169
Other comprehensive income (loss)	$ 0	0	0	39	$ 0	39
Balances (in shares) at Jun. 30, 2021	24,084,000				(3,518,000)
Ending balance at Jun. 30, 2021	$ 2	87,213	(42,554)	39	$ 0	44,700
Balances (in shares) at Mar. 31, 2021	23,915,000				(3,518,000)
Beginning balance at Mar. 31, 2021	$ 2	86,163	(43,374)	158	$ 0	42,949
Stock-based shares issued upon vesting - gross (in shares)	180,000				0
Stock-based shares issued upon vesting - gross	$ 0	0	0	0	$ 0	0
Stock-based compensation expense	$ 0	254	0	0	$ 0	254
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)	(27,000)				0
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	$ 0	(576)	0	0	$ 0	(576)
Net income	$ 0	0	820	0	$ 0	820
Employee stock purchase plan (in shares)	16,000				0
Employee stock purchase plan	$ 0	1,372	0	0	$ 0	1,372
Other comprehensive income (loss)	$ 0	0	0	(119)	$ 0	(119)
Balances (in shares) at Jun. 30, 2021	24,084,000				(3,518,000)
Ending balance at Jun. 30, 2021	$ 2	$ 87,213	$ (42,554)	$ 39	$ 0	$ 44,700

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
OPERATING ACTIVITIES
Net income	$ 1,481	$ 3,722
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	(109)	523
Depreciation	5,090	4,782
Loss on disposal of and reserve adjustments for medical equipment	640	77
Gain on sale of medical equipment	(375)	(3,224)
Amortization of intangible assets	2,139	2,150
Amortization of deferred debt issuance costs	114	9
Stock-based compensation	3,007	563
Deferred income taxes	(658)	12
Changes in assets - (increase)/decrease:
Accounts receivable	(329)	(2,115)
Inventories	(647)	(1,363)
Other current assets	138	205
Other assets	(70)	(123)
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities	(1,607)	(956)
NET CASH PROVIDED BY OPERATING ACTIVITIES	8,814	4,262
INVESTING ACTIVITIES
Acquisition of business	(7,490)	0
Purchase of medical equipment	(4,943)	(8,783)
Purchase of property and equipment	(334)	(680)
Proceeds from sale of medical equipment, property and equipment	1,503	971
NET CASH USED IN INVESTING ACTIVITIES	(11,264)	(8,492)
FINANCING ACTIVITIES
Principal payments on long-term debt	(53,982)	(23,777)
Cash proceeds from long-term debt	47,913	26,259
Debt issuance costs	(386)	0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans	(1,141)	(741)
Cash proceeds from stock plans	562	74
Common stock - issued	0	250
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(7,034)	2,065
Net change in cash and cash equivalents	(9,484)	(2,165)
Cash and cash equivalents, beginning of period	9,648	2,647
Cash and cash equivalents, end of period	$ 164	$ 482

Note 1 - Basis of Presentation,

Note 1 - Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not not may 10 December 31, 2020 March 22, 2021. The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. Derivatives Accounting Policy The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (“AOCI”) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities. The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis. The fair values of the Company’s derivative financial instruments are categorized as Level 2

Note 2 - Recent Accounting Pron

Note 2 - Recent Accounting Pronouncements and Developments	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. Recent Accounting Pronouncements and Developments In June 2016, No. 2016 13, 326 326 not 326 January 1, 2020, November 2019, December 15, 2022 326

Note 3 - Business Combinations

Note 3 - Business Combinations	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Business Combinations Acquisitions Accounted for Using the Purchase Method On January 31, 2021, On April 18, 2021, FilAMed and OB Healthcare’s results of operations are included in the Company’s consolidated statements of operations from the respective closing dates. Revenues and earnings from these acquisitions has not June 30, 2021. Purchase Price Allocation Pursuant to FASB Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, June 30, 2021. may FilAMed OB Healthcare Total Consideration Cash $ 1,400 $ 6,250 $ 7,650 Working capital (a) - 328 328 Contingent consideration - 750 750 Total - consideration $ 1,400 $ 7,328 $ 8,728 FilAMed OB Healthcare Total Acquisition Date Fair Value Accounts receivable (a) $ - $ 727 $ 727 Inventories 74 - 74 Medical equipment held for sale or rental 40 - 40 Property and equipment 102 59 161 Intangible assets 1,015 3,000 4,015 Goodwill 169 3,542 3,711 Operating lease right of use assets 281 7 288 Operating lease liabilities (281 ) (7 ) (288 ) Total - purchase price (a) $ 1,400 $ 7,328 $ 8,728 (a) Amount based on preliminary working capital During the three June 30, 2021, three June 30, 2021. On the FilAMed acquisition date, the Company made an initial cash payment of $1.2 million with a remaining liability of $0.2 million, which was paid during the quarter ended June 30, 2021. $0.8 December 31, 2021. June 30, 2021, The following table shows the breakdown of the identified intangible assets acquired into major intangible asset classes for both acquisitions: Acquisition Date Fair Value (Thousands) Weighted-Average Amortization Period (Years) Customer relationships $ 2,300 15 Unpatented technology 943 7 Non-competition agreements 472 5 Internal-use software 300 5 Total intangible assets (a) $ 4,015 11.2 (a) There was no The goodwill acquired consists of expected synergies from combining operations of FilAMed and OB Healthcare with the DME Services segment as well as their respective assembled workforce who have specialized knowledge and experience. All of the goodwill is deductible for tax purposes. Unaudited Pro Forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results of operations of the Company, FilAMed and OB Healthcare as though the companies’ businesses had been combined as of the beginning of the three six June 30, 2020. three six June 30, 2021 three six June 30, 2020 not three six June 30, 2021 2020 Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Revenue $ 25,035 $ 26,835 $ 50,067 $ 49,538 Net income $ 1,001 $ 3,743 $ 990 $ 3,489

Note 4 - Revenue Recognition

Note 4 - Revenue Recognition	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. Revenue Recognition The following table presents the Company’s disaggregated revenue by offering type (in thousands): Three Months Ended June 30, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 13,130 52.9 % $ 12,752 49.0 % Direct Payer Rentals 8,354 33.6 % 7,940 30.6 % Product Sales 3,350 13.5 % 5,307 20.4 % Total $ 24,834 100.0 % $ 25,999 100.0 % Six Months Ended June 30, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 25,924 52.6 % $ 23,988 50.5 % Direct Payer Rentals 16,440 33.3 % 14,800 31.1 % Product Sales 6,933 14.1 % 8,764 18.4 % Total $ 49,297 100.0 % $ 47,552 100.0 % Third-Party Payer Rentals are entirely attributed to revenues of the Integrated Therapy Services (“ITS”) segment. Product Sales are entirely attributed to revenues of the DME Services segment. For the three June 30, 2021, three June 30, 2020, For the six June 30, 2021, six June 30, 2020,

Note 5 - Medical Equipment

Note 5 - Medical Equipment	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Medical Equipment and Property Disclosure [Text Block]	5. Medical Equipment Medical equipment consisted of the following (in thousands): June 30, December 31, 2021 2020 Medical equipment for sale or rental $ 3,010 $ 1,636 Medical equipment for sale or rental - pump reserve (55 ) (33 ) Medical equipment for sale or rental - net 2,955 1,603 Medical equipment in rental service 85,959 83,411 Medical equipment in rental service - pump reserve (1,286 ) (893 ) Accumulated depreciation (49,272 ) (46,907 ) Medical equipment in rental service - net 35,401 35,611 Total $ 38,356 $ 37,214 Depreciation expense for medical equipment for the three six June 30, 2021

Note 6 - Property and Equipment

Note 6 - Property and Equipment	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following (in thousands): June 30, 2021 December 31, 2020 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 4,183 $ (2,256 ) $ 1,927 $ 3,742 $ (2,018 ) $ 1,724 Automobiles 117 (108 ) 9 117 (102 ) 15 Leasehold improvements 3,418 (1,035 ) 2,383 3,416 (859 ) 2,557 Total $ 7,718 $ (3,399 ) $ 4,319 $ 7,275 $ (2,979 ) $ 4,296 Depreciation expense for property and equipment for the three six June 30, 2021 $0.2

Note 7 - Goodwill & Intangible

Note 7 - Goodwill & Intangible Assets	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	7. Goodwill & Intangible Assets The changes in the carrying value of goodwill by segment for the six June 30, 2021 DME Services (a) Balance as of December 31, 2020 $ - Goodwill acquired 3,711 Balance as of June 30, 2021 $ 3,711 (a) No goodwill allocated to the ITS segment The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands): June 30, 2021 December 31, 2020 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ - $ 2,000 $ 2,000 $ - $ 2,000 Amortizable intangible assets: Trade names 23 (23 ) - 23 (23 ) - Physician and customer relationships 38,834 (30,137 ) 8,697 36,534 (28,924 ) 7,610 Non-competition agreements 472 (20 ) 452 - - - Unpatented technology 943 (56 ) 887 - - - Software 11,530 (10,513 ) 1,017 11,230 (9,663 ) 1,567 Total nonamortizable and amortizable intangible assets $ 53,802 $ (40,749 ) $ 13,053 $ 49,787 $ (38,610 ) $ 11,177 Amortization expense for the three six June 30, 2021 five June 30, 2021 2026 and 2021 2022 2023 2024 2025 thereafter Total Amortization expense $ 2,123 $ 2,494 $ 990 $ 990 $ 810 $ 3,646 $ 11,053

Note 8 - Debt

Note 8 - Debt	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Debt On February 5, 2021, “2021 2021 The 2021 February 5, 2026. may 2021 may February 5, 2021, March 23, 2015 ( “2015 The 2021 ● a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 2021 four 1.00; ● a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four 1.00. The 2021 Simultaneous with the execution of the 2021 first On February 5, 2021, 2021 2015 2015 2015 2015 2021 At December 31, 2020, 2015 November 9, 2024, three December 31, 2020. December 31, 2020 30 December 31, 2020 December 31, 2020 The 2021 June 30, 2021, 2021 On April 15, 2019, third not 842. June 30, 2021 As referenced above, the Company executed and closed the 2021 first 2021, 2015 June 30, 2021 2021 December 31, 2020 2015 June 30, December 31, 2021 2020 Revolving Facility: Gross availability $ 75,000 $ 11,750 Outstanding draws (32,203 ) - Letter of credit (800 ) (800 ) Landlord reserves - (162 ) Availability on Revolving Facility $ 41,997 $ 10,788 The Company had future maturities of its long-term debt as of June 30, 2021 2021 2022 2023 2024 2025 and thereafter Total Revolving Facility $ - $ - $ - $ - $ 32,203 $ 32,203 Other financing 372 222 - - - 594 Total $ 372 $ 222 $ - $ - $ 32,203 $ 32,797 The following is a breakdown of the Company’s current and long-term debt (in thousands): June 30, 2021 December 31, 2020 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ - $ 32,203 32,203 $ - $ - $ - Term loan - - - 4,615 17,305 21,920 Equipment line - - - 1,600 4,400 6,000 2019 equipment line - - - 2,500 7,500 10,000 Other financing 594 - 594 725 222 947 594 32,203 32,797 9,440 29,427 38,867 Unamortized value of debt issuance costs (74 ) (263 ) (337 ) (17 ) (49 ) (66 ) Total $ 520 $ 31,940 $ 32,460 $ 9,423 $ 29,378 $ 38,801 As of June 30, 2021, 2021 June 30, 2021 June 30, 2021

Note 9 - Derivative Financial I

Note 9 - Derivative Financial Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	9. Derivative Financial Instruments and Hedging Activities During the quarter ended March 31, 2021, not The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 February 2021, two five February 5, 2026. 30 not The table below presents the location and gross fair value amounts of our derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands): June 30, 2021 (a) Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Other noncurrent assets $ 20,000 $ 52 (a) No December 31, 2020. The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 (a) 2021 (a) Gain/(loss) on cash flow hedges - interest rate swaps Beginning balance $ 158 $ - Unrealized gain/(loss) recognized in AOCI (137 ) 11 Amounts reclassified to interest expense (b)( c) 31 41 Tax provision (13 ) (13 ) Ending balance $ 39 $ 39 (a) No three six June 30, 2020 (b) Positive amounts represented interest expense. Total interest expense as presented in the consolidated statement of operations for the three six June 30, 2021 (c) $0.1 million of expense is expected to be reclassified into earnings within the next 12 The Company did not three six June 30, 2021.

Note 10 - Income Taxes

Note 10 - Income Taxes	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes During the three six June 30, 2021, three six June 30, 2020, On March 27, 2020, 19 June 30, 2021. $0.7 two December 31, 2021 2022,

Note 11 - Commitments, Continge

Note 11 - Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may may not not, not not The Company is not

Note 12 - Earnings Per Share

Note 12 - Earnings Per Share	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Earnings Per Share Basic income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income per share computations: Three Months Ended June 30, Six Months Ended June 30, Numerator: 2021 2020 2021 2020 Net income (in thousands) $ 820 $ 4,140 $ 1,481 $ 3,722 Denominator: Weighted average common shares outstanding: Basic 20,487,845 20,082,590 20,413,416 20,000,444 Dilutive effect of common stock equivalents 1,577,641 1,553,115 1,604,039 1,597,627 Diluted 22,065,486 21,635,705 22,017,455 21,598,071 Net income per share: Basic $ 0.04 $ 0.21 $ 0.07 $ 0.19 Diluted $ 0.04 $ 0.19 $ 0.07 $ 0.17 For the three six June 30, 2021, not three six June 30, 2020, not Share Repurchase Program On June 30, 2021, June 30, 2024. 2021 may may 10b5 1 not may June 30, 2021, not

Note 13 - Leases

Note 13 - Leases	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	13. Leases The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next ten not one five not not not not Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may The components of lease costs for the three six June 30, 2021 2020 Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Operating lease cost $ 348 $ 404 $ 696 $ 828 Variable lease cost 58 77 115 189 Total lease cost $ 406 $ 481 $ 811 $ 1,017 Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands): Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities and right of use assets: Operating cash flow from operating leases $ 720 $ 789 Right of use assets obtained in exchange for lease obligations: Operating leases $ 288 $ 118 Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows: As of June 30, 2021 2020 Years Years Weighted average remaining lease term: 6.5 7.2 Rate Rate Weighted average discount rate: 7.7 % 7.8 % Future maturities of lease liabilities as of June 30, 2021 Operating Leases 2021 $ 545 2022 1,183 2023 979 2024 949 2025 914 Thereafter 2,253 Total undiscounted lease payments 6,823 Less: Imputed interest (2,327 ) Total lease liabilities $ 4,496

Note 14 - Business Segment Info

Note 14 - Business Segment Information	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Business Segment Information The Company’s reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by third The financial information summarized below is presented by reportable segment for the three June 30, 2021 2020: 2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 16,334 $ 8,500 $ - $ 24,834 Net revenues - internal - 1,598 (1,598 ) - Total net revenues 16,334 10,098 (1,598 ) 24,834 Gross profit 10,451 4,599 - 15,050 Selling, general and administrative expenses 14,354 14,354 Interest expense (317 ) (317 ) Other expense (37 ) (37 ) Benefit from income taxes 478 478 Net income $ 820 Total assets $ 60,876 $ 33,121 $ 2,000 $ 95,997 Purchases of medical equipment $ 1,871 $ 736 $ - $ 2,607 Depreciation and amortization of intangible assets $ 2,732 $ 927 $ - $ 3,659 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 15,605 $ 10,394 $ - $ 25,999 Net revenues - internal - 1,258 (1,258 ) - Total net revenues 15,605 11,652 (1,258 ) 25,999 Gross profit 10,279 5,699 - 15,978 Selling, general and administrative expenses 11,472 11,472 Interest expense (332 ) (332 ) Other expense (9 ) (9 ) Provision for income taxes (25 ) (25 ) Net income $ 4,140 Total assets $ 51,962 $ 30,007 $ 2,000 $ 83,969 Purchases of medical equipment $ 2,663 $ 2,113 $ - $ 4,776 Depreciation and amortization of intangible assets $ 2,694 $ 836 $ - $ 3,530 The financial information summarized below is presented by reportable segment for the six June 30, 2021 2020: 2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 32,245 $ 17,052 $ - $ 49,297 Net revenues - internal - 3,044 (3,044 ) - Total net revenues 32,245 20,096 (3,044 ) 49,297 Gross profit 20,454 9,172 - 29,626 Selling, general and administrative expenses 28,057 28,057 Interest expense (639 ) (639 ) Other expense (106 ) (106 ) Benefit from income taxes 657 657 Net income $ 1,481 Total assets $ 60,876 $ 33,121 $ 2,000 $ 95,997 Purchases of medical equipment $ 3,492 $ 1,451 $ - $ 4,943 Depreciation and amortization of intangible assets $ 5,428 $ 1,801 $ - $ 7,229 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 29,731 $ 17,821 $ - $ 47,552 Net revenues - internal - 2,496 (2,496 ) - Total net revenues 29,731 20,317 (2,496 ) 47,552 Gross profit 19,385 9,256 - 28,641 Selling, general and administrative expenses 24,102 24,102 Interest expense (735 ) (735 ) Other expense (28 ) (28 ) Provision for income taxes (54 ) (54 ) Net income $ 3,722 Total assets $ 51,962 $ 30,007 $ 2,000 $ 83,969 Purchases of medical equipment $ 5,020 $ 3,763 $ - $ 8,783 Depreciation and amortization of intangible assets $ 5,348 $ 1,584 $ - $ 6,932

Note 15 - COVID-19

Note 15 - COVID-19	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Effect of Covid-19 Pandemic [Text Block]	15. COVID- 19 On March 11, 2020, 19” may 19, 19 not three six June 30, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Derivatives, Policy [Policy Text Block]	Derivatives Accounting Policy The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (“AOCI”) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities. The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis. The fair values of the Company’s derivative financial instruments are categorized as Level 2

Note 3 - Business Combinations

Note 3 - Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	FilAMed OB Healthcare Total Consideration Cash $ 1,400 $ 6,250 $ 7,650 Working capital (a) - 328 328 Contingent consideration - 750 750 Total - consideration $ 1,400 $ 7,328 $ 8,728
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	FilAMed OB Healthcare Total Acquisition Date Fair Value Accounts receivable (a) $ - $ 727 $ 727 Inventories 74 - 74 Medical equipment held for sale or rental 40 - 40 Property and equipment 102 59 161 Intangible assets 1,015 3,000 4,015 Goodwill 169 3,542 3,711 Operating lease right of use assets 281 7 288 Operating lease liabilities (281 ) (7 ) (288 ) Total - purchase price (a) $ 1,400 $ 7,328 $ 8,728
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Acquisition Date Fair Value (Thousands) Weighted-Average Amortization Period (Years) Customer relationships $ 2,300 15 Unpatented technology 943 7 Non-competition agreements 472 5 Internal-use software 300 5 Total intangible assets (a) $ 4,015 11.2
Business Acquisition, Pro Forma Information [Table Text Block]	Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Revenue $ 25,035 $ 26,835 $ 50,067 $ 49,538 Net income $ 1,001 $ 3,743 $ 990 $ 3,489

Note 4 - Revenue Recognition (T

Note 4 - Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 13,130 52.9 % $ 12,752 49.0 % Direct Payer Rentals 8,354 33.6 % 7,940 30.6 % Product Sales 3,350 13.5 % 5,307 20.4 % Total $ 24,834 100.0 % $ 25,999 100.0 % Six Months Ended June 30, 2021 2020 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Third-Party Payer Rentals $ 25,924 52.6 % $ 23,988 50.5 % Direct Payer Rentals 16,440 33.3 % 14,800 31.1 % Product Sales 6,933 14.1 % 8,764 18.4 % Total $ 49,297 100.0 % $ 47,552 100.0 %

Note 5 - Medical Equipment (Tab

Note 5 - Medical Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Medical Equipment [Table Text Block]	June 30, December 31, 2021 2020 Medical equipment for sale or rental $ 3,010 $ 1,636 Medical equipment for sale or rental - pump reserve (55 ) (33 ) Medical equipment for sale or rental - net 2,955 1,603 Medical equipment in rental service 85,959 83,411 Medical equipment in rental service - pump reserve (1,286 ) (893 ) Accumulated depreciation (49,272 ) (46,907 ) Medical equipment in rental service - net 35,401 35,611 Total $ 38,356 $ 37,214

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2021 December 31, 2020 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 4,183 $ (2,256 ) $ 1,927 $ 3,742 $ (2,018 ) $ 1,724 Automobiles 117 (108 ) 9 117 (102 ) 15 Leasehold improvements 3,418 (1,035 ) 2,383 3,416 (859 ) 2,557 Total $ 7,718 $ (3,399 ) $ 4,319 $ 7,275 $ (2,979 ) $ 4,296

Note 7 - Goodwill & Intangibl_2

Note 7 - Goodwill & Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Goodwill [Table Text Block]	DME Services (a) Balance as of December 31, 2020 $ - Goodwill acquired 3,711 Balance as of June 30, 2021 $ 3,711
Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block]	June 30, 2021 December 31, 2020 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ - $ 2,000 $ 2,000 $ - $ 2,000 Amortizable intangible assets: Trade names 23 (23 ) - 23 (23 ) - Physician and customer relationships 38,834 (30,137 ) 8,697 36,534 (28,924 ) 7,610 Non-competition agreements 472 (20 ) 452 - - - Unpatented technology 943 (56 ) 887 - - - Software 11,530 (10,513 ) 1,017 11,230 (9,663 ) 1,567 Total nonamortizable and amortizable intangible assets $ 53,802 $ (40,749 ) $ 13,053 $ 49,787 $ (38,610 ) $ 11,177
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2026 and 2021 2022 2023 2024 2025 thereafter Total Amortization expense $ 2,123 $ 2,494 $ 990 $ 990 $ 810 $ 3,646 $ 11,053

Note 8 - Debt (Tables)

Note 8 - Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Line of Credit Facilities [Table Text Block]	June 30, December 31, 2021 2020 Revolving Facility: Gross availability $ 75,000 $ 11,750 Outstanding draws (32,203 ) - Letter of credit (800 ) (800 ) Landlord reserves - (162 ) Availability on Revolving Facility $ 41,997 $ 10,788
Schedule of Maturities of Long-term Debt [Table Text Block]	2021 2022 2023 2024 2025 and thereafter Total Revolving Facility $ - $ - $ - $ - $ 32,203 $ 32,203 Other financing 372 222 - - - 594 Total $ 372 $ 222 $ - $ - $ 32,203 $ 32,797
Schedule of Debt [Table Text Block]	June 30, 2021 December 31, 2020 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ - $ 32,203 32,203 $ - $ - $ - Term loan - - - 4,615 17,305 21,920 Equipment line - - - 1,600 4,400 6,000 2019 equipment line - - - 2,500 7,500 10,000 Other financing 594 - 594 725 222 947 594 32,203 32,797 9,440 29,427 38,867 Unamortized value of debt issuance costs (74 ) (263 ) (337 ) (17 ) (49 ) (66 ) Total $ 520 $ 31,940 $ 32,460 $ 9,423 $ 29,378 $ 38,801

Note 9 - Derivative Financial_2

Note 9 - Derivative Financial Instruments and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	June 30, 2021 (a) Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Other noncurrent assets $ 20,000 $ 52
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2021 (a) 2021 (a) Gain/(loss) on cash flow hedges - interest rate swaps Beginning balance $ 158 $ - Unrealized gain/(loss) recognized in AOCI (137 ) 11 Amounts reclassified to interest expense (b)( c) 31 41 Tax provision (13 ) (13 ) Ending balance $ 39 $ 39

Note 12 - Earnings Per Share (T

Note 12 - Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, Numerator: 2021 2020 2021 2020 Net income (in thousands) $ 820 $ 4,140 $ 1,481 $ 3,722 Denominator: Weighted average common shares outstanding: Basic 20,487,845 20,082,590 20,413,416 20,000,444 Dilutive effect of common stock equivalents 1,577,641 1,553,115 1,604,039 1,597,627 Diluted 22,065,486 21,635,705 22,017,455 21,598,071 Net income per share: Basic $ 0.04 $ 0.21 $ 0.07 $ 0.19 Diluted $ 0.04 $ 0.19 $ 0.07 $ 0.17

Note 13 - Leases (Tables)

Note 13 - Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Operating lease cost $ 348 $ 404 $ 696 $ 828 Variable lease cost 58 77 115 189 Total lease cost $ 406 $ 481 $ 811 $ 1,017 Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities and right of use assets: Operating cash flow from operating leases $ 720 $ 789 Right of use assets obtained in exchange for lease obligations: Operating leases $ 288 $ 118 As of June 30, 2021 2020 Years Years Weighted average remaining lease term: 6.5 7.2 Rate Rate Weighted average discount rate: 7.7 % 7.8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Leases 2021 $ 545 2022 1,183 2023 979 2024 949 2025 914 Thereafter 2,253 Total undiscounted lease payments 6,823 Less: Imputed interest (2,327 ) Total lease liabilities $ 4,496

Note 14 - Business Segment In_2

Note 14 - Business Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 16,334 $ 8,500 $ - $ 24,834 Net revenues - internal - 1,598 (1,598 ) - Total net revenues 16,334 10,098 (1,598 ) 24,834 Gross profit 10,451 4,599 - 15,050 Selling, general and administrative expenses 14,354 14,354 Interest expense (317 ) (317 ) Other expense (37 ) (37 ) Benefit from income taxes 478 478 Net income $ 820 Total assets $ 60,876 $ 33,121 $ 2,000 $ 95,997 Purchases of medical equipment $ 1,871 $ 736 $ - $ 2,607 Depreciation and amortization of intangible assets $ 2,732 $ 927 $ - $ 3,659 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 15,605 $ 10,394 $ - $ 25,999 Net revenues - internal - 1,258 (1,258 ) - Total net revenues 15,605 11,652 (1,258 ) 25,999 Gross profit 10,279 5,699 - 15,978 Selling, general and administrative expenses 11,472 11,472 Interest expense (332 ) (332 ) Other expense (9 ) (9 ) Provision for income taxes (25 ) (25 ) Net income $ 4,140 Total assets $ 51,962 $ 30,007 $ 2,000 $ 83,969 Purchases of medical equipment $ 2,663 $ 2,113 $ - $ 4,776 Depreciation and amortization of intangible assets $ 2,694 $ 836 $ - $ 3,530 2021 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 32,245 $ 17,052 $ - $ 49,297 Net revenues - internal - 3,044 (3,044 ) - Total net revenues 32,245 20,096 (3,044 ) 49,297 Gross profit 20,454 9,172 - 29,626 Selling, general and administrative expenses 28,057 28,057 Interest expense (639 ) (639 ) Other expense (106 ) (106 ) Benefit from income taxes 657 657 Net income $ 1,481 Total assets $ 60,876 $ 33,121 $ 2,000 $ 95,997 Purchases of medical equipment $ 3,492 $ 1,451 $ - $ 4,943 Depreciation and amortization of intangible assets $ 5,428 $ 1,801 $ - $ 7,229 2020 Corporate/ (in thousands) ITS DME Services Eliminations Total Net revenues - external $ 29,731 $ 17,821 $ - $ 47,552 Net revenues - internal - 2,496 (2,496 ) - Total net revenues 29,731 20,317 (2,496 ) 47,552 Gross profit 19,385 9,256 - 28,641 Selling, general and administrative expenses 24,102 24,102 Interest expense (735 ) (735 ) Other expense (28 ) (28 ) Provision for income taxes (54 ) (54 ) Net income $ 3,722 Total assets $ 51,962 $ 30,007 $ 2,000 $ 83,969 Purchases of medical equipment $ 5,020 $ 3,763 $ - $ 8,783 Depreciation and amortization of intangible assets $ 5,348 $ 1,584 $ - $ 6,932

Note 3 - Business Combination_2

Note 3 - Business Combinations (Details Textual) - USD ($) $ in Thousands	Apr. 18, 2021	Jan. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021
Payments to Acquire Businesses, Gross					$ 7,650
Business Acquisition, Pro Forma Acquisition Cost and Non-recurring Expense						$ 100
FilAMed [Member]
Payments to Acquire Businesses, Gross		$ 1,200		$ 200	1,400
Acquisition of OB Healthcare [Member]
Payments to Acquire Businesses, Gross	$ 6,100		$ 6,250
Business Combination, Contingent Consideration, Liability, Total			$ 1,200	1,200	$ 1,200	$ 1,200
Acquisition of OB Healthcare [Member] | Other Current Liabilities [Member]
Business Combination, Working Capital Adjustment	500
Business Combination, Contingent Consideration, Liability, Total	$ 800
General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs				$ 100

Note 3 - Business Combination_3

Note 3 - Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Thousands		Apr. 18, 2021	Jan. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2021
Cash						$ 7,650
Working capital (a)	[1]					328
Contingent consideration						750
Total - consideration						8,728
FilAMed [Member]
Cash			$ 1,200		$ 200	1,400
Working capital (a)	[1]					0
Contingent consideration						0
Total - consideration						$ 1,400
Acquisition of OB Healthcare [Member]
Cash		$ 6,100		$ 6,250
Working capital (a)	[1]			328
Contingent consideration				750
Total - consideration				$ 7,328
[1]	Amount based on preliminary working capital

Note 3 - Business Combination_4

Note 3 - Business Combinations - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands		Jun. 30, 2021	Apr. 18, 2021	Jan. 31, 2021	Dec. 31, 2020
Accounts receivable (a)	[1]	$ 727
Inventories		74
Medical equipment held for sale or rental		40
Property and equipment		161
Intangible assets		4,015
Goodwill		3,711			$ 0
Operating lease right of use assets		288
Operating lease liabilities		(288)
Total - purchase price (a)	[1]	$ 8,728
FilAMed [Member]
Accounts receivable (a)	[1]			$ 0
Inventories				74
Medical equipment held for sale or rental				40
Property and equipment				102
Intangible assets				1,015
Goodwill				169
Operating lease right of use assets				281
Operating lease liabilities				(281)
Total - purchase price (a)	[1]			$ 1,400
Acquisition of OB Healthcare [Member]
Accounts receivable (a)	[1]		$ 727
Inventories			0
Medical equipment held for sale or rental			0
Property and equipment			59
Intangible assets			3,000
Goodwill			3,542
Operating lease right of use assets			7
Operating lease liabilities			(7)
Total - purchase price (a)	[1]		$ 7,328
[1]	Amount based on preliminary working capital

Note 3 - Business Combination_5

Note 3 - Business Combinations - Intangible Assets Acquired (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Intangible assets	$ 4,015
Intangible assets, weighted average amortization period (Year)	11 years 2 months 12 days
Customer Relationships [Member]
Intangible assets	$ 2,300
Intangible assets, weighted average amortization period (Year)	15 years
Technology-Based Intangible Assets [Member]
Intangible assets	$ 943
Intangible assets, weighted average amortization period (Year)	7 years
Noncompete Agreements [Member]
Intangible assets	$ 472
Intangible assets, weighted average amortization period (Year)	5 years
Computer Software, Intangible Asset [Member]
Intangible assets	$ 300
Intangible assets, weighted average amortization period (Year)	5 years

Note 3 - Business Combination_6

Note 3 - Business Combinations - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 25,035	$ 26,835	$ 50,067	$ 49,538
Net income	$ 1,001	$ 3,743	$ 990	$ 3,489

Note 4 - Revenue Recognition (D

Note 4 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues, Total	$ 24,834	$ 25,999	$ 49,297	$ 47,552
Direct Payer Rentals [Member]
Revenues, Total	8,354	7,940	16,440	14,800
Direct Payer Rentals [Member] | ITS Segment [Member]
Revenues, Total	3,200	2,800	6,300	5,700
Direct Payer Rentals [Member] | DME Services Segment [Member]
Revenues, Total	$ 5,200	$ 5,100	$ 10,100	$ 9,100

Note 4 - Revenue Recognition -

Note 4 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues, Total	$ 24,834	$ 25,999	$ 49,297	$ 47,552
Percentage of total net revenues	100.00%	100.00%	100.00%	100.00%
Third-Party Payor Rental Revenue [Member]
Revenues, Total	$ 13,130	$ 12,752	$ 25,924	$ 23,988
Percentage of total net revenues	52.90%	49.00%	52.60%	50.50%
Direct Payer Rentals [Member]
Revenues, Total	$ 8,354	$ 7,940	$ 16,440	$ 14,800
Percentage of total net revenues	33.60%	30.60%	33.30%	31.10%
Product Sales [Member]
Revenues, Total	$ 3,350	$ 5,307	$ 6,933	$ 8,764
Percentage of total net revenues	13.50%	20.40%	14.10%	18.40%

Note 5 - Medical Equipment (Det

Note 5 - Medical Equipment (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Depreciation Expense Related to Medical Equipment	$ 2.3	$ 2.3	$ 4.6	$ 4.4

Note 5 - Medical Equipment - Su

Note 5 - Medical Equipment - Summary of Medical Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Medical equipment for sale or rental	$ 3,010	$ 1,636
Medical equipment for sale or rental - pump reserve	(55)	(33)
Medical equipment for sale or rental - net	2,955	1,603
Medical equipment in rental service	85,959	83,411
Medical equipment in rental service - pump reserve	(1,286)	(893)
Accumulated depreciation	(49,272)	(46,907)
Medical equipment in rental service - net	35,401	35,611
Total	$ 38,356	$ 37,214

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Depreciation, Nonproduction	$ 0.3	$ 0.2	$ 0.5	$ 0.4

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Gross Assets	$ 7,718	$ 7,275
Accumulated Depreciation	(3,399)	(2,979)
Total	4,319	4,296
Furniture and Fixtures [Member]
Gross Assets	4,183	3,742
Accumulated Depreciation	(2,256)	(2,018)
Total	1,927	1,724
Automobiles [Member]
Gross Assets	117	117
Accumulated Depreciation	(108)	(102)
Total	9	15
Leasehold Improvements [Member]
Gross Assets	3,418	3,416
Accumulated Depreciation	(1,035)	(859)
Total	$ 2,383	$ 2,557

Note 7 - Goodwill & Intangibl_3

Note 7 - Goodwill & Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Goodwill, Ending Balance	$ 3,711		$ 3,711		$ 0
Amortization of Intangible Assets, Total	1,096	$ 1,075	2,139	$ 2,150
ITS Segment [Member]
Goodwill, Ending Balance	$ 0		$ 0

Note 7 - Goodwill & Intangibl_4

Note 7 - Goodwill & Intangible Assets - Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Balance as of December 31, 2020	$ 0
Balance as of June 30, 2021	3,711
DME Services Segment [Member]
Balance as of December 31, 2020	0	[1]
Goodwill acquired	3,711	[1]
Balance as of June 30, 2021	$ 3,711	[1]
[1]	No goodwill allocated to the ITS segment

Note 7 - Goodwill & Intangibl_5

Note 7 - Goodwill & Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Amortizable intangible assets, accumulated amortization	$ (40,749)	$ (38,610)
Amortizable intangible assets, net	11,053
Total nonamortizable and amortizable intangible assets, gross assets	53,802	49,787
Total nonamortizable and amortizable intangible assets, net	13,053	11,177
Trade Names [Member]
Amortizable intangible assets, gross assets	23	23
Amortizable intangible assets, accumulated amortization	(23)	(23)
Amortizable intangible assets, net	0	0
Physician and Customer Relationships [Member]
Amortizable intangible assets, gross assets	38,834	36,534
Amortizable intangible assets, accumulated amortization	(30,137)	(28,924)
Amortizable intangible assets, net	8,697	7,610
Noncompete Agreements [Member]
Amortizable intangible assets, gross assets	472	0
Amortizable intangible assets, accumulated amortization	(20)	0
Amortizable intangible assets, net	452	0
Technology-Based Intangible Assets [Member]
Amortizable intangible assets, gross assets	943	0
Amortizable intangible assets, accumulated amortization	(56)	0
Amortizable intangible assets, net	887	0
Computer Software, Intangible Asset [Member]
Amortizable intangible assets, gross assets	11,530	11,230
Amortizable intangible assets, accumulated amortization	(10,513)	(9,663)
Amortizable intangible assets, net	1,017	1,567
Trade Names 1 [Member]
Nonamortizable intangible assets	$ 2,000	$ 2,000

Note 7 - Goodwill & Intangibl_6

Note 7 - Goodwill & Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) $ in Thousands	Jun. 30, 2021USD ($)
Amortization expense, 2021	$ 2,123
Amortization expense, 2022	2,494
Amortization expense, 2023	990
Amortization expense, 2024	990
Amortization expense, 2025	810
Amortization expense, 2026 and thereafter	3,646
Amortization expense, Total	$ 11,053

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) $ in Thousands	Feb. 05, 2021USD ($)	Apr. 15, 2019USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Feb. 04, 2020USD ($)
Revolving Credit Facility [Member]
Long-term Line of Credit, Total			$ 32,203	$ 0
Letters of Credit Outstanding, Amount			800	800
Line of Credit Facility, Current Borrowing Capacity			$ 75,000	11,750
The 2021 Credit Agreement [Member]
Percentage of Total Depreciation Expense	50.00%
Debt Instrument, Covenant, Minimum Fixed Coverage Ratio	1.20
Debt Instrument, Covenant, Maximum Leverage Ratio	3.50
The 2021 Credit Agreement [Member] | Eurodollar Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage			2.08%
LIBOR Rate			0.08%
The 2021 Credit Agreement [Member] | ABR Loans [Member]
Debt Instrument, Interest Rate, Effective Percentage			4.25%
Lender Prime Rate			3.25%
The 2021 Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate			2.00%
The 2021 Credit Agreement [Member] | Base Rate [Member] | ABR Loans [Member]
Debt Instrument, Basis Spread on Variable Rate			1.00%
The 2021 Credit Agreement [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate			2.00%
The 2021 Credit Agreement [Member] | Minimum [Member] | Base Rate [Member] | ABR Loans [Member]
Debt Instrument, Basis Spread on Variable Rate			1.00%
The 2021 Credit Agreement [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate			3.00%
The 2021 Credit Agreement [Member] | Maximum [Member] | Base Rate [Member] | ABR Loans [Member]
Debt Instrument, Basis Spread on Variable Rate			2.00%
The 2021 Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 75,000
Line of Credit Facility, Additional Borrowing Capacity Subject to Certain Conditions	25,000
Proceeds from Long-term Lines of Credit	30,000
The 2021 Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	7,000
The 2015 Credit Agreement [Member]
Long-term Line of Credit, Total					$ 800
The 2015 Credit Agreement [Member] | Revolving Credit Facility [Member]
Repayments of Long-term Lines of Credit	$ 8,200
Three Term Notes Associated With the 2015 Credit Agreement [Member]
Debt Instrument, Face Amount				$ 37,900
Credit Facility [Member] | Eurodollar Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage				2.19%
LIBOR Rate				0.19%
Credit Facility [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage				2.25%
Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				2.00%
Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Basis Spread on Variable Rate, Before Margin Rate				2.50%
Credit Facility [Member] | CB Floating Rate [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				(1.00%)
Lender Prime Rate				3.25%
Credit Facility [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				2.00%
Credit Facility [Member] | Minimum [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				(1.00%)
Credit Facility [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Eurodollar Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				3.00%
Credit Facility [Member] | Maximum [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member] | CB Floating Rate Loan [Member]
Debt Instrument, Basis Spread on Variable Rate				0.25%
Credit Facility [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 11,800
Letters of Credit Outstanding, Amount				1,000
Line of Credit Facility, Borrowing Base				$ 15,600
Financing Agreement [Member] | Medical Equipment [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,000
Debt Instrument, Term (Month)		36 months
Line of Credit Facility, Current Borrowing Capacity			$ 600

Note 8 - Debt - Summary of Revo

Note 8 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Gross availability	$ 75,000	$ 11,750
Outstanding draws	(32,203)	0
Letter of credit	(800)	(800)
Landlord reserves	0	(162)
Availability on Revolving Facility	$ 41,997	$ 10,788

Note 8 - Debt - Summary of Futu

Note 8 - Debt - Summary of Future Maturities of Loans (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
2021	$ 372
2022	222
2023	0
2024	0
2025 and thereafter	32,203
Total	32,797	$ 38,867
Financing Agreement [Member]
2021	372
2022	222
2023	0
2024	0
2025 and thereafter	0
Total	594	947
Revolving Credit Facility [Member]
2021	0
2022	0
2023	0
2024	0
2025 and thereafter	32,203
Total	$ 32,203	$ 0

Note 8 - Debt - Summary of Comp

Note 8 - Debt - Summary of Company's Current and Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Long-term debt, current portion, gross	$ 594	$ 9,440
Long-term debt, noncurrent portion, gross	32,203	29,427
Total, gross	32,797	38,867
Unamortized value of the debt issuance costs, current portion of long-term debt	(74)	(17)
Unamortized value of the debt issuance costs, long-term debt	(263)	(49)
Unamortized value of the debt issuance costs, Total	(337)	(66)
Current portion of long-term debt	520	9,423
Long-term debt	31,940	29,378
Total	32,460	38,801
Financing Agreement [Member]
Long-term debt, current portion, gross	594	725
Long-term debt, noncurrent portion, gross	0	222
Total, gross	594	947
Term Loan [Member]
Long-term debt, current portion, gross	0	4,615
Long-term debt, noncurrent portion, gross	0	17,305
Total, gross	0	21,920
Revolving Credit Facility [Member]
Long-term debt, current portion, gross	0	0
Long-term debt, noncurrent portion, gross	32,203	0
Total, gross	32,203	0
Equipment Line [Member]
Long-term debt, current portion, gross	0	1,600
Long-term debt, noncurrent portion, gross	0	4,400
Total, gross	0	6,000
The 2019 Equipment Line [Member]
Long-term debt, current portion, gross	0	2,500
Long-term debt, noncurrent portion, gross	0	7,500
Total, gross	$ 0	$ 10,000

Note 9 - Derivative Financial_3

Note 9 - Derivative Financial Instruments and Hedging Activities (Details Textual) $ in Thousands	Feb. 05, 2021	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Interest Expense, Total		$ 317	$ 332	$ 639	$ 735
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]
Derivative, Number of Instruments Held, Total	2
Derivative, Term of Contract (Year)	5 years
Derivative, Fixed Interest Rate	0.73%
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months				100
Derivative, Net Hedge Ineffectiveness Gain (Loss)		$ 0		$ 0

Note 9 - Derivative Financial_4

Note 9 - Derivative Financial Instruments and Hedging Activities - Fair Value and Notional Amounts of Cash Flow Hedges (Details) - Cash Flow Hedging [Member] - Interest Rate Swap [Member] - Designated as Hedging Instrument [Member] - Other Current Assets [Member] $ in Thousands	Jun. 30, 2021USD ($)	[1]
Notional	$ 20,000
Fair Value Derivative Assets	$ 52
[1]	No derivative instruments existed at December 31, 2020.

Note 9 - Derivative Financial_5

Note 9 - Derivative Financial Instruments and Hedging Activities - Derivative Financial Instruments Designated as Hedging Instruments in AOCI (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
		Jun. 30, 2021	Jun. 30, 2021
Beginning balance		$ 42,949	$ 40,752
Ending balance		44,700	44,700
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Beginning balance	[1]	158	0
Unrealized gain/(loss) recognized in AOCI	[1]	(137)	11
Amounts reclassified to interest expense (b)( c)	[1],[2],[3]	31	41
Tax provision	[1]	(13)	(13)
Ending balance	[1]	$ 39	$ 39
[1]	No derivative instruments existed for the three and six months ended June 30, 2020
[2]	$0.1 million of expense is expected to be reclassified into earnings within the next 12 months
[3]	Positive amounts represented interest expense. Total interest expense as presented in the consolidated statement of operations for the three months and six months ended June 30, 2021 were $0.3 million and $0.6 million, respectively

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Expense (Benefit), Total	$ (478)	$ 25	$ (657)	$ 54
Other Liabilities [Member]
Accrued Payroll Taxes	$ 700		$ 700
Maximum [Member]
Income Tax Expense (Benefit), Total		$ 100		$ 100

Note 12 - Earnings Per Share (D

Note 12 - Earnings Per Share (Details Textual) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.2	0.1	0.1	0.1
Stock Repurchase Program, Authorized Amount	$ 20		$ 20

Note 12 - Earnings Per Share -

Note 12 - Earnings Per Share - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net income (loss)	$ 820	$ 4,140	$ 1,481	$ 3,722
Weighted average common shares outstanding:
Basic (in shares)	20,487,845	20,082,590	20,413,416	20,000,444
Dilutive effect of common stock equivalents (in shares)	1,577,641	1,553,115	1,604,039	1,597,627
Diluted (in shares)	22,065,486	21,635,705	22,017,455	21,598,071
Basic (in dollars per share)	$ 0.04	$ 0.21	$ 0.07	$ 0.19
Diluted (in dollars per share)	$ 0.04	$ 0.19	$ 0.07	$ 0.17

Note 13 - Leases (Details Textu

Note 13 - Leases (Details Textual) - Office Leases With Renewal Options Not Reasonably Certain to Exercise [Member]	Jun. 30, 2021
Minimum [Member]
Lessee, Operating Lease, Renewal Term (Year)	1 year
Maximum [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 13 - Leases - Lease Cost (

Note 13 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating lease cost	$ 348	$ 404	$ 696	$ 828
Variable lease cost	58	77	115	189
Total lease cost	$ 406	$ 481	811	1,017
Operating cash flow from operating leases			720	789
ROU assets obtained in exchange for lease obligations: Operating leases			$ 288	$ 118
Weighted average remaining lease term: (Year)	6 years 6 months	7 years 2 months 12 days	6 years 6 months	7 years 2 months 12 days
Weighted average discount rate:	7.70%	7.80%	7.70%	7.80%

Note 13 - Leases - Maturities o

Note 13 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2021USD ($)
2021	$ 545
2022	1,183
2023	979
2024	949
2025	914
Thereafter	2,253
Total undiscounted lease payments	6,823
Less: Imputed interest	(2,327)
Total lease liabilities	$ 4,496

Note 14 - Business Segment In_3

Note 14 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Net revenues - external	$ 24,834	$ 25,999	$ 49,297	$ 47,552
Net revenues - internal	0	0	0	0
Total net revenues	24,834	25,999	49,297	47,552
Gross profit	15,050	15,978	29,626	28,641
Selling, general and administrative expenses	14,354	11,472	28,057	24,102
Interest expense	(317)	(332)	(639)	(735)
Other expense	(37)	(9)	(106)	(28)
Benefit from income taxes	478	(25)	657	(54)
Net income	820	4,140	1,481	3,722
Total assets	95,997	83,969	95,997	83,969	$ 96,991
Purchases of medical equipment	2,607	4,776	4,943	8,783
Depreciation and amortization of intangible assets	3,659	3,530	7,229	6,932
Net income	820	4,140	1,481	3,722
Corporate and Eliminations [Member]
Net revenues - external	0	0	0	0
Net revenues - internal	(1,598)	(1,258)	(3,044)	(2,496)
Total net revenues	(1,598)	(1,258)	(3,044)	(2,496)
Gross profit	0	0	0	0
Selling, general and administrative expenses	14,354	11,472	28,057	24,102
Interest expense	(317)	(332)	(639)	(735)
Other expense	(37)	(9)	(106)	(28)
Benefit from income taxes	478	(25)	657	(54)
Total assets	2,000	2,000	2,000	2,000
Purchases of medical equipment	0	0	0	0
Depreciation and amortization of intangible assets	0	0	0	0
ITS Segment [Member] | Operating Segments [Member]
Net revenues - external	16,334	15,605	32,245	29,731
Net revenues - internal	0	0	0	0
Total net revenues	16,334	15,605	32,245	29,731
Gross profit	10,451	10,279	20,454	19,385
Total assets	60,876	51,962	60,876	51,962
Purchases of medical equipment	1,871	2,663	3,492	5,020
Depreciation and amortization of intangible assets	2,732	2,694	5,428	5,348
DME Services Segment [Member] | Operating Segments [Member]
Net revenues - external	8,500	10,394	17,052	17,821
Net revenues - internal	1,598	1,258	3,044	2,496
Total net revenues	10,098	11,652	20,096	20,317
Gross profit	4,599	5,699	9,172	9,256
Total assets	33,121	30,007	33,121	30,007
Purchases of medical equipment	736	2,113	1,451	3,763
Depreciation and amortization of intangible assets	$ 927	$ 836	$ 1,801	$ 1,584